Shigehira Saji

21PUBLICATIONS
128CO-AUTHORS
Environmental epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Tissue engineeringPharmacogenomicsAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jul 08, 2026
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.

|Jun 10, 2026
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.

|Mar 19, 2026
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.

Norikazu Masuda, Hiroyuki Yasojima, Hiroko Bando

|Dec 17, 2025
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy.

Hope S Rugo, David W Cescon, Mark E Robson

|Dec 16, 2025
Author Correction: Advancing equitable access to innovation in breast cancer.

Seamus O'Reilly, Ines Vaz Luis, Virginie Adam

|Nov 22, 2025
The safety and effectiveness of pegfilgrastim to reduce cancer chemotherapy-induced febrile neutropenia in real-world practice in Japan: a post-marketing surveillance study.

Nobuhiro Shibata, Hiroshi Kuwazawa, Tomoharu Yasukawa

Pageof 4

Frequent Collaborators

8 joint publications

Norikazu Masuda

7 joint publications

Satoshi Morita

4 joint publications

Masato Takahashi

3 joint publications

Takayuki Ueno